Highlights {#s001}
==========

1.  • In people with type 1 diabetes, on a previously intensified treatment, we confirm that the use of a bolus calculator can reduce the hypoglycemic episodes for the short term.

2.  • For the long term (8 months) a bolus calculator does not improve further the overall metabolic control, but some psychological aspects, such as the fear of hypoglycemia and satisfaction with the treatment, can still get better.

Introduction {#s002}
============

I[n subjects with]{.smallcaps} type 1 diabetes (DM1) on treatment intensification, either with multiple daily injections of insulin (MDI) or a continuous subcutaneous insulin infusion (CSII), it is necessary to properly calculate the insulin bolus, both for prandial and corrective insulin. That calculation includes variables such as carbohydrate count (CH), management of insulin/CH ratio (CarbF), or insulin sensitivity factor (ISF), all of which require personalization and can be complicated. A published study demonstrated that people with DM1 on treatment with MDI did not correctly calculate the majority of bolus.^[@B1]^ The use of bolus calculators (BCs) allows the patient to obtain a more precise and personalized recommended insulin dose by means of a preprogrammed system. In people with diabetes on treatment with CSII, this is already part of the standard clinical practice. The introduction of BCs for people on treatment with MDI, combined with blood glucose monitors or apps for smartphones, is relatively recent. With the use of BCs, the subject depends on a device to help him make decisions concerning the treatment, which involves a process of learning, adaptation, and the building of confidence, all of which may involve added stress.

The BC contribution to the improvement of metabolic control and its impact on psychological issues such as fear of hypoglycemia and level of treatment satisfaction is documented in recent publications.^[@B2]^ We will only quote studies performed in people on MDI (not CSII) treatment. Two randomized clinical trials (CTs) are compulsory references, both performed with the Accu-Chek^®^ Aviva Expert device: (1) The BolusCal study,^[@B4]^ in which in both intervention groups (measuring CH, with or without the use of a BC) an improvement in HbA1c was observed (−0.8% and −0.7% reduction, respectively), although without significant differences between them. There were no differences between groups regarding hypoglycemic episodes. (2) The ABACUS (Automated Bolus Advisor Control and Usability Study) revealed that more patients who used a BC managed to reduce their HbA1c \>0.5% compared with the control group (56% vs. 34.4%; *P* \< 0.001); however, an increase in hypoglycemia (\<70 mg/dL) was found.^[@B5],[@B7]^

A recent publication, the Expert study, shows how the use of a BC also allowed a significant reduction in HbA1c (although similar to the one obtained in the active control group) associated with a decrease in postprandial hypoglycemia (\<60 mg/dL).^[@B6]^

With reference to the psychological evaluation, at the end of the BolusCal study the people who used the BC obtained better scores on treatment satisfaction, with no significant differences observed with regard to fear of hypoglycemia.^[@B4]^ In the ABACUS study a significant improvement was also noted in treatment satisfaction compared with the control group; however the evaluation of the remaining psychological variables, such as fear of hypoglycemia, has not been published yet.^[@B5],[@B7]^ In the Expert study a significant improvement in quality of life and satisfaction with the use of BC was observed.^[@B6]^

Recently we have published the results of a CT in which subjects were randomized to use a BC or to a control group for 4 months.^[@B10]^ Both groups were active in the handling of concepts related with prandial bolus calculation (CH measuring, CarbF, ISF, etc.), although only one of them used the device. We observed a significant decrease in HbA1c compared with baseline in both groups. A significant decrease in the total number of hypoglycemic episodes was found only in the group that used the BC. There were no significant differences regarding fear of hypoglycemia or treatment satisfaction.^[@B10]^

The aim of this article is to evaluate whether the extension of the treatment with BC (from 4 to 8 months) or the introduction of it in the previously intensified control group could mean an additional improvement in glycemic control or hypoglycemic episodes or changes in the related psychological issues.

Methods {#s003}
=======

The participants in this study came from a clinical trial (CBMDI study, Calculating Boluses on Multiple Daily Injections) performed by the Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, which evaluated the metabolic and psychological effects of the incorporation of a BC in DM1 people on MDI treatment. The study, including this extension, was approved by the Investigation Ethics Committee of the Hospital Regional Universitario of Málaga, and conforms to the provisions of the Declaration of Helsinki. The patients had been randomized to use a BC (Cb group) or to be in the active control group (Co group) during 4 months. People with DM1 \> 18 years old, with HbA1c \>7%, on treatment with basal-bolus therapy, and not having suffered from more than two severe hypoglycemic episodes in the precedent year were included. We used the device Accu-Chek Aviva Expert BC (Roche Diagnostics, Indianapolis, IN). The results presented in this study were obtained from the extension of the previous study for a further 4 months, in which all participants were joined in a single group, all of them using the BC. The control group (Co group), which was starting using the BC (Co→Cb group), was trained in its use in the last visit of the previous phase of the study, and had, as was previously done with the Cb group, an additional visit 2 weeks afterward to ensure the correct use of the device. Subsequently both groups had two scheduled visits, after 2 and 4 months. The same protocol was followed in both visits as in the previous study (educational support, downloading the self-monitoring of blood glucose \[SMBG\] from the 2 weeks before the visit, adjustment of the basal insulin dose, and modification of the programming of CarbF and ISF). Furthermore, the tools of psychological evaluation were applied, and an analytical extraction was made at the start and end of the second phase (fourth and eighth month).

The variables initially collected were sex, age, years of diabetes evolution, and education level. With regard to metabolic control, we evaluated HbA1c and its modifications, and from the 2 weeks before each visit (through downloaded SMBG registers) we checked mean glycemia (total, pre- and postprandial) and number of major hyperglycemia (\>250 mg/dL) and hypoglycemia (\<70 and \<50 mg/dL, pre- and postprandial and nocturnal) episodes; we also recorded the number of severe and moderate hypoglycemic events \[defined, respectively, as (1) severe: loss of consciousness, having used glucagon, or requiring professional healthcare attention; (2) moderate: with the need of help from a third person, but resolved with oral glucose\] for all the study period. Estimations of glycemic variability were also calculated (SD, CV, MAGE, LBGI, and HBGI).

Unless the participant was using a personalized CarbF and/or ISF before the beginning of the study, these factors were established, respectively, in 1 IU/KE and 50 mg/(dL·IU).

The changes in CarbF (IU/KE) and ISF (mg/dL of glycemia reduced by 1 extra IU) throughout the study were likewise recorded.

A questionnaire was included, as in the first phase of the study, to show the frequency of use and acceptance of the BC (basal, 4 and 8 months). The questionnaire was adapted from the "Device Utilization by the Patient" from the ProAct study^[@B11]^ with the authorization of Roche Diabetes Care. It consists of nine questions with a score of answers ranging from 1 to 5 (5 being the highest score).

Treatment satisfaction was evaluated by means of the Spanish version^[@B12]^ of the Diabetes Treatment Satisfaction Questionnaire (DTSQ),^[@B13]^ with two versions to be completed, at the start (DTSQs) and after the treatment/follow-up (DTSQc). A higher score represents a higher level of satisfaction. The participants also fulfilled the Fear of Hypoglycemia FH-15 questionnaire,^[@B14]^ which consists of 15 items with an answer scale ranging between 1 and 5. A sum of scores ≥28 is considered indicative of fear of hypoglycemia.

Statistical study {#s004}
-----------------

The sample size was calculated for the previous CT, having being estimated at 82 subjects.^[@B10]^ The sample of the present study stems from the acceptance of the participants to extend the previous study.

We present the results of an intention to treat analysis. Continuous variables were summarized using mean and SD values; categorical variables were summarized using counts and percentages of patients in each category. To test hypothesis, the Student\'s *t* test for continuous variables with normal distribution, nonparametric test (Mann--Whitney or Wilcoxon) in the case of continuous variables that did not conform to normal, and the *χ*^2^ for the association between proportions were performed. To check changes over time, the McNemar test was used for proportions, and the one way ANOVA with repeated measures was used for continuous variables. Linear regression models were performed to explain the relationship of dependence among some variables. The alpha error to reject null hypothesis was 0.05 for two tails.

Results {#s005}
=======

In [Figure 1](#f1){ref-type="fig"} the flow of participants in the study is shown, including the first 4 month randomized CT phase, the results of which have already been published. We are presenting mainly the results of the second phase of the study, this is, from the fourth to the eighth month. Forty-two subjects started this phase coming from the group that had already been using the BC (Cb group); 28 subjects came from the control group (Co group) and started using the BC (Co→Cb group). Sixty-five participants completed the study (38 and 27, respectively).

![Flow chart of subjects during the study.](fig-1){#f1}

There were no differences between groups in the general characteristics of the subjects (sex, age, and years of DM evolution) at the start of the second phase of the study (25 females/17 males in Cb group, 13 females/15 males in Co→Cb group, *P* 0.281; aged 30.69 ± 12.19 years in Cb group vs. 34.21 ± 12.09 years in Co→Cb group, *P* 0.239; duration of DM 14.76 ± 9.79 years in Cb group vs. 16.18 ± 8.46 in Co→Cb group, *P* 0.534).

Metabolic control was not different between groups at the beginning of the study; it improved for both groups at the fourth month (published data) and did not improve further during the study extension up to 8 months, either in patients who extended the use of the BC from 4 to 8 months or in those patients (with previously intensified treatment) to whom the use of the BC was added. HbA1c even looked to increase slightly from 4 to 8 months, although not significantly, and was not different between groups ([Table 1](#T1){ref-type="table"}). But if we considered the whole sample (Cb + Co→Cb) and divided it into two groups, this is, participants that just before using BC had a HbA1c ≥ or \<8.5%, they showed a different behavior regarding metabolic control. People having a HbA1c ≥8.5% just before using BC reduced the HbA1c significantly after 4 months of having used it (9.18% ± 0.67% vs. 8.29% ± 0.97%, *P* \< 0.001). The reduction in the HbA1c for participants with a basal figure \<8.5% was not significant (7.63 ± 0.41 vs. 7.58 ± 0.59, *P* 0.58). The same behavior was found regarding HbA1c ≥ or \<8%.

###### 

[Metabolic Control: 4--8 Months (Second Phase of the Study)]{.smallcaps}

                                                      *Cb group*       *Co→Cb group*                                                                                                           
  --------------------------------------------------- ---------------- ----------------------------------------------- ------- --------------- ----------------------------------------------- -------
  HbA1c (%)                                           7.61 ± 0.58      7.73 ± 0.65                                     0.209   7.86 ± 0.87     8.01 ± 0.93                                     0.215
  Change HbA1c (%)                                                     +0.12 ± 0.56                                                            +0.15 ± 0.6                                      
  No. of SMBG tests/day                               4.75 ± 0.92      4.77 ± 1.07                                     0.886   5.16 ± 1.19     4.87 ± 1.2                                      0.219
  Glycemia (mg/dL)                                                                                                                                                                             
   Total                                              159.8 ± 21.8     163.9 ± 21.0^[†](#tf2){ref-type="table-fn"}^    0.294   171.4 ± 28.8    176.5 ± 28.2^[†](#tf2){ref-type="table-fn"}^    0.218
   Preprandial                                        160.4 ± 23.0     161.9 ± 22.9 ^[‡](#tf2){ref-type="table-fn"}^   0.682   169.1 ± 30.5    176.8 ± 32.7 ^[‡](#tf2){ref-type="table-fn"}^   0.077
   Postprandial                                       166.8 ± 32.8     166.0 ± 24.1^[§](#tf2){ref-type="table-fn"}^    0.358   175.7 ± 39.3    181.7 ± 35.5^[§](#tf2){ref-type="table-fn"}^    0.301
  No. of hypoglycemic episodes/2 weeks                                                                                                                                                         
   Total                                              7.1 ± 4.0        7.8 ± 4.2^[\*\*](#tf2){ref-type="table-fn"}^    0.426   5.9 ± 4.1       4.7 ± 3.5^[\*\*](#tf2){ref-type="table-fn"}^    0.162
   Preprandial                                        4.5 ± 3.3        4.7 ± 3.1                                       0.759   3.1 ± 2.7       3.7 ± 2.9                                       0.407
   Postprandial                                       1.9 ± 1.5        2.2 ± 2.1^[††](#tf2){ref-type="table-fn"}^      0.468   2.3 ± 2.0       1.1 ± 1.2^[††](#tf2){ref-type="table-fn"}^      0.002
   Nocturnal                                          0.7 ± 0.8        0.8 ± 1.4                                       0.571   0.5 ± 0.8       0.8 ± 1.0                                       0.313
   \<50 mg/dL                                         1.8 ± 1.9        1.6 ± 1.8^[‡‡](#tf2){ref-type="table-fn"}^      0.938   1.1 ± 1.3       1.0 ± 1.3^[‡‡](#tf2){ref-type="table-fn"}^      0.511
  No. of hyperglycemic episodes \>250 mg/dL/2 weeks                                                                                                                                            
                                                      8.23 ± 5.77      8.94 ± 5.54                                     0.536   11.77 ± 6.67    11.92 ± 7.01                                    0.914
  SD total (mg/dL)                                    72.8 ± 14.21     78.35 ± 16.1                                    0.008   81.16 ± 23.61   78.91 ± 10.05                                   0.456
  CV (%)                                              45.82 ± 8.81     47.69 ± 7.66                                    0.124   46.88 ± 7.83    44.60 ± 6.43                                    0.114
  MAGE (mg/dL)                                        144.85 ± 55.16   140.78 ± 64.97                                  0.749   157.1 ± 51.81   139.75 ± 56.64                                  0.215
  LBGI                                                2.75 ± 1.62      2.65 ± 1.26                                     0.738   1.95 ± 1.12     2.38 ± 3.67                                     0.555
  HBGI                                                8.50 ± 4.23      10.38 ± 5.55                                    0.057   10.83 ± 5.33    10.63 ± 5.07                                    0.854
  Insulin \[IU/(kg·d)\]                                                                                                                                                                        
   Basal                                              0.56 ± 0.24      0.53 ± 0.22                                     0.009   0.65 ± 0.28     0.64 ± 0.27                                     0.232
   Prandial                                           0.32 ± 0.11      0.32 ± 0.12                                     0.834   0.33 ± 0.09     0.34 ± 0.09                                     0.784
   Total                                              0.88 ± 0.29      0.85 ± 0.27                                     0.045   0.96 ± 0.31     0.95 ± 0.31                                     0.374

Mean ± SD.

*P* intragroups. Between groups at 8 months: ^†^*P* 0.045; ^‡^*P* 0.035; ^§^*P* 0.032; ^\*\*^*P* 0.003; ^††^*P* 0.006; and ^‡‡^*P* 0.026.

Cb, BC group; Co, control group; CV, coefficient of variation; HBGI, high blood glucose index; LBGI, low blood glucose index; MAGE, mean amplitude of glycemic excursions; SD, standard deviation.

The results obtained in a linear regression model, in which the dependent variable was HbA1c at 4 and 8 months, can be seen in the [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. HbA1c at 4 months (the end of the previous CT) could be explained in terms of variables such as age, education level, basal HbA1c, and also the treatment group belonged to (favoring the use of BC). In this extension phase, in the multivariate study, only previous HbA1c (4 months) and the number of daily SMBG could be associated with the HbA1c at 8 months. Given that all the participants at 8 months were using the BC, there was no option to differentiate by treatment group.

###### 

[Linear Regression Model HbA1c at 4 Months]{.smallcaps}

  *Model*           B        *Std err*   *Beta*   t        P       *Adj R*^2^
  ----------------- -------- ----------- -------- -------- ------- ------------
  Basal HbA1c       0.452    0.084       0.480    5.393    0.000   0.505
  Education level   −0.238   0.074       −0.283   −3.199   0.002    
  Age (years)       −0.016   0.006       −0.251   −2.827   0.006    
  Treatment group   −0.289   0.139       −0.181   −2.086   0.041    

Sex, SMBG tests at 4 months, No. of hypoglycemic episodes at 4 months, and BMI did not enter in the model significantly.

###### 

[Linear Regression Model HbA1c at 8 Months]{.smallcaps}

  *Model*             B        *SE*    *Beta*   t        P       *Adj R*^2^
  ------------------- -------- ------- -------- -------- ------- ------------
  HbA1c 4 months      0.723    0.096   0.666    7.517    0.000   0.530
  No. of SMBG tests   −0.144   0.066   −0.192   −2.167   0.034    

Group of treatment, sex, age, basal HbA1c, level of education, No. of hypoglycemic episodes at 4 months, and BMI did not enter in the model significantly. SE, standard error.

In the Co→Cb group, after having used the BC for 4 months, postprandial hypoglycemia episodes were significantly reduced. This group also had at 8 months less total and postprandial hypoglycemia and \<50 mg/dL than the Cb group ([Table 1](#T1){ref-type="table"}). Again for the whole sample, if we divided it into two groups, participants that just before using BC had a HbA1c ≥ or \<8.5%, hypoglycemic events behaved differently. After using the BC for 4 months, the reduction in the total hypoglycemic events reached significance for participants with a HbA1c \<8.5% (7.71 ± 4.70 vs. 6.00 ± 4.21/2 weeks, *P* 0.03). For participants with a HbA1c ≥8.5% before using BC it showed a trend toward reduction, not reaching significance (6.76 ± 4.35 vs. 5.48 ± 3.63/2 weeks, *P* 0.10).

In a regression model, with the number of hypoglycemic episodes at 8 months as the dependent variable, the number of basal hypoglycemia, the evolution of DM (in years), and the treatment group formed a significant part of the model explanation ([Table 4](#T4){ref-type="table"}).

###### 

[Linear Regression Model No. of Hypoglycemic Episodes at 8 Months]{.smallcaps}

  *Model*                               B        *Std err*   *Beta*   t       P       *Adj R*^2^
  ------------------------------------- -------- ----------- -------- ------- ------- ------------
  No. of hypoglycemic episodes, basal   0.270    0.098       0.300    2.752   0.008   0.588
  Duration of DM (years)                −0.149   0.048       −0.335   3.126   0.003    
  Treatment group                       2.417    0.905       −0.289   2.671   0.010    

Alcohol and ISF did not enter in the model significantly.

DM, diabetes mellitus.

During this phase, three episodes of severe hypoglycemia (in two participants of the Cb group) and two moderate hypoglycemia (one in the Cb group and one in the Co→Cb group) were recorded. None of the subjects affected had a similar precedent during the year before the study. During the second phase of the study nine participants with precedents of such hypoglycemic episodes in the previous year (five in the Cb group and four in the Co group) completed the study period without having suffered from severe or moderate hypoglycemic episodes.

Regarding major hyperglycemia events (\>250 mg/dL), no differences were observed between groups or within them at 8 months ([Table 1](#T1){ref-type="table"}).

Only for the Cb group the SD of glycemia was slightly but significantly increased from the fourth to the eighth months. Estimations of glycemic variability such as MAGE, LBGI, or HBGI did not show any significant changes during the study, either between or within groups ([Table 1](#T1){ref-type="table"}).

A reduction in the number of postprandial SMBG tests at the end of the study regarding baseline was observed for both groups, although it was only significant in the group that used BC for 8 months (Cb group, baseline 2.07 ± 0.59 per day, vs. 8 months 1.59 ± 0.72, *P* \< 0.001).

The mean CarbF for breakfast, lunch, and dinner was, respectively, 1.34 ± 0.64, 1.17 ± 0.46, and 1.16 ± 0.43 IU/KE before using the BC and 1.50 ± 0.69, 1.10 ± 0.52, and 1.18 ± 0.44 at the end of the study. These differences were significant for breakfast (*P* 0.002). The mean ISF before using the BC, for the same meals, was, respectively, 45.88 ± 8.82, 45.61 ± 10.26, and 46.06 ± 9.3 mg/dL and 40.86 ± 13.99, 43.72 ± 12.28, and 42.83 ± 13.42 at the end of the study. These differences were also significant for breakfast (*P* 0.005).

For all the participants, when comparing the distribution of the CarbF from before using the BC to the end of the study, significantly more subjects switched to an increase of the CarbF (\>1) for breakfast and showed a trend to decrease the CarbF for lunch; the ISF was also significantly reduced (\<50) for breakfast and dinner for the same period ([Fig. 2](#f2){ref-type="fig"}).

![Changes in CarbF and ISF from before BC to the end of the study (8 months). BC, bolus calculator; ISF, insulin sensitivity factor.](fig-2){#f2}

The treatment satisfaction improved significantly in the group that had been using the BC for all the 8 months compared with the group that had used it only for 4 months; regarding the fear of hypoglycemia, a significant improvement was observed compared with baseline only in the Cb group ([Fig. 3](#f3){ref-type="fig"}). The use and acceptance of the BC got high scores at the end of the study for all the asked items ([Fig. 4](#f4){ref-type="fig"}).

![DTSQc (Diabetes Treatment Satisfaction Questionnaire-change) and FH-15 (Fear of Hypoglycemia). 4m, 4 months; 8m, 8 months. \**P* \< 0.05.](fig-3){#f3}

![Acceptance questionnaire about using the BC (all subjects, 8 months).](fig-4){#f4}

Twenty-one participants (24%) were lost (dropout and withdrawal) during the follow-up, most of them (*n* = 16) in the first phase of the study. Twelve belonged to the Co group and 9 to the Cb group, without overall differences between groups, but most participants from the Co group leaving the study did it in the first phase (*n* = 11/12) ([Fig. 1](#f1){ref-type="fig"}).

No differences were found in age, sex, and duration of DM in the patients who completed the study compared with those who did not. Basal HbA1c was significantly higher in the participants who left the study (8.71% ± 1.02% vs. 8.28% ± 0.80%, *P* 0.048); they also had higher basal mean total and preprandial glycemia (180.28 ± 43.06 mg/dL vs. 164.27 ± 23.67 mg/dL, *P* 0.047; 177.33 ± 46.88 mg/dL vs. 158.54 ± 25.39 mg/dL, *P* 0.034) and performed less daily SMBG tests at baseline (4.74 ± 1.38 vs. 5.37 ± 1.02, *P* 0.043).

Discussion {#s006}
==========

People with DM1 treated with flexible insulin treatment face the challenge of performing complicated calculations before deciding what insulin bolus dose to take. This process includes the application of concepts such as the CarbF, ISF, and residual active insulin.^[@B15]^ BCs facilitate these calculations; however they require training, reprogramming, follow-up, and confidence in the proposed insulin dose. Several studies have shown the impact of this technology on the psychological well-being and metabolic control of people with DM1 treated with MDI.^[@B3]^

In the first phase of our study we had demonstrated a significant decrease in HbA1c for the group treated with BC during 4 months (−0.66%) and also for the active control group (−0.39%).^[@B10]^ Although HbA1c or its decrease was not significantly different between groups in the bivariate comparisons, in a linear regression model the treatment group was significant to explain the decrease of the HbA1c. Besides that, the group treated with BC significantly reduced hypoglycemic episodes.^[@B10]^

During this second phase of the study the implementation and use of BCs in the control group during 4 months did not produce any additional improvement in the glycemic control compared with the previous period. Starting out from an intensified treatment, it was probably going to be difficult to achieve any additional improvement. In the group that had been wearing the BC for all the 8 months of the study there was not a further reduction in the HbA1c, rather it was only maintained. Probably the effect of any treatment intensification on glycemic control could be demonstrated in the short term, but at medium term only its maintenance can be expected.^[@B11]^ The ABACUS study, which was 26 weeks long, is the one that was closest to ours in terms of time; they started out with a higher basal HbA1c (8.9% vs. 8.4% in our study) meaning that its decrease with intervention was potentially more feasible,^[@B5]^ due to the known fact that initial HbA1c has an influence on the change.^[@B16]^ This is supported by the fact that, in our study, HbA1c improved mainly in the subgroup of participants that had a figure ≥8.5% before using BC.

The incorporation of the BC in the control group led to a decrease of postprandial hypoglycemic episodes, just as we found in the first phase of the study, when the total hypoglycemia was reduced in the Cb group^[@B10]^; that is to say, in both groups the incorporation of the BC achieved some reduction in hypoglycemia. This improvement was found mainly for the subgroup of participants on a better basal metabolic control (HbA1c \<8.5%). In the regression study, the type of treatment proved to be significant in explaining the hypoglycemia. It is possible that the hypoglycemic episodes were reduced due to a better individualization of ISF and because the BC programming takes the active insulin into account; both could have avoided overdoses of corrective insulin. In the Expert study,^[@B6]^ performed in our area also in subjects with DM1 on treatment with MDI, a reduction in postprandial hypoglycemia was also found. Another Study in a pediatric population also showed a reduction in hypoglycemia.^[@B17]^ The ABACUS study on the contrary showed more total hypoglycemia in the group that used the BC.^[@B5]^ In the BolusCal study no differences for hypoglycemia were found between treatment groups.^[@B4]^ Historically, the risk of many forms of treatment intensification in DM is the increase in the rate of hypoglycemia episodes, mostly severe ones.^[@B18]^ Therefore the BC can be considered to be a useful tool for treatment intensification without increasing, or even (according to our study) achieving a discreet but significant reduction in hypoglycemic episodes.

With the use of the BC, contrary to what could be expected, the subjects reduced the number of SMBG tests, and less postprandial SMBG tests were recorded than the number requested from the study protocol. The postprandial glycemia allegedly would be modifiable or more affected by the introduction of a BC and could then be biased; probably the patients performed fewer postprandial SMBG tests because they thought they were being well controlled and therefore they did not deem it necessary, limiting the SMBG tests to less representative moments, this could be, when hyperglycemia or hypoglycemia was suspected. Including a larger group of participants, a higher number of visits or the use of a CGM (continuous glucose monitor) could have provided more data, but the latter could not be included in the study due to the lack of funding. In the ABACUS study the number of daily SMBG tests were maintained throughout the study in both groups^[@B19]^; in the Expert study, in which also a continuous glucose monitoring system was used, the number of daily SMBG tests increased significantly with the use of BC.^[@B6]^

In the subjects from the Cb group, at the eighth month, the glycemic variability measured by SD increased compared with the fourth month. This could be due to the slight decrease in the number of SMBG tests, which could have been performed more often in situations when hyper- or hypoglycemia was suspected, thereby explaining the greater dispersion in the glycemia obtained. The ABACUS study described a reduction in MAGE in people treated with BC,^[@B5]^ while in the Expert study no significant differences were found regarding glycemic variability.^[@B6]^

The CarbF throughout the study was increased significantly for breakfast. Regarding ISF, it was reduced throughout the study to nearly 40 mg/dL, figure we suggest to be applied more widely.

In the participants who used the BC during all the study (Cb group) a significant reduction in the fear of hypoglycemia was observed at 8 months compared with the basal situation. Only in one study, performed also in people with DM1 on treatment with MDI, a similar improvement was found.^[@B3]^ In the BolusCal study no differences in the fear of hypoglycemia were proved,^[@B4]^ but the questionnaire used was the Hypoglycemic Fear Scale (HFS), different to the one used in our study (FH-15). The analysis of the fear of hypoglycemia in the ABACUS study has not been published yet.^[@B5]^ In the Expert study fear of hypoglycemia was not evaluated.^[@B6]^

At the end of our study (8 months) an improvement in treatment satisfaction was observed only in the group that had been using the BC from the start (Cb group). Similar results were also observed in other studies with BC and CSII^[@B2],[@B20],[@B21],[@B22]^ or MDI.^[@B4],[@B5]^

The losses in the Co group occurred mostly early in the study, and in the Cb group later, during the follow-up. The initial dropouts could be due to the disappointment for not having been included in the Cb group from the outset of the study, which concurs with the interpretation of the investigators in the ABACUS study.^[@B9]^ There were no dropouts or withdrawals due to the difficulty of using the device, in fact, the participants considered the BC easy to learn and use, as can be seen in the scores of the questionnaires on the use of the BC.

Among the limitations of this study we highlight the high percentage of dropouts. The group that did not complete the study, irrespective of the moment of dropping out, presented a worse metabolic control at baseline, with a higher HbA1c. These types of subjects are those who could theoretically further improve HbA1c with any type of intervention.^[@B16]^ The highest percentage of dropouts that initially affected the Co group could have biased this group toward the more reliable participants. In contrast some participants performed few postprandial SMBG and others reduced them during the study, thereby making the reprogramming of the CarbF and ISF more difficult to perform, which could have also negatively affected the potential efficiency of the BC on metabolic control and hypoglycemia. As strength, we could highlight the prospective randomized and controlled design of our study and that its duration (8 months, greater than other studies) has enabled us to prove psychological benefits than were not shown in the short term and to verify that the improvement obtained in the HbA1c can be sustained over time.

In conclusion, compared with the first part of the study (in which both the group treated with BC and the control group improved their glycemic control), the extension of the follow-up to 8 months could not obtain a greater benefit concerning glycemic control (HbA1c), but rather could only maintain it. As had been observed in the group who used the BC in the first 4 months of the study, the control group that was incorporated in the use of the device also achieved a significant reduction in hypoglycemic episodes. Furthermore, in the subjects in which the use of the BC was extended to 8 months, a greater treatment satisfaction was observed and likewise a reduction in the fear of hypoglycemia. The subjects considered the BC to be a well valued tool which they could trust and they used it to make the majority of their decisions concerning insulin bolus.
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